About the transaction

With the acquisition of Lusomedicamenta for around EUR 112 million, which followed the acquisition of Italienska Corvette, Recipharm has created one of Europe’s leading contract manufacturers of medicinal products. Before these acquisitions, the company had a smaller business in Spain and through the acquisition, Recipharm gained access to new clients, markets and technologies along with a strong position in southwestern Europe. Lusomedicamenta had a number of distribution agreements on the Portuguese market with companies such as Boehringer Ingelheim, Gedeon Richter and OM Pharma (Vifor). Translink represented the sellers in the transaction.

Director Niklas Wilhelmsson from Anecta was the advisor in the transaction.

Anecta’s comments

This is an example of how we can create an exclusive dialogue for Swedish business groups through strong local presence even in markets that are difficult to access. Anecta, exclusive partner in the Translink network, initiated the deal by proposing it to Recipharm. Translink represented the sellers in the transaction. The acquisition multiple more than doubled during negotiations.

- Niklas Wilhelmsson

Nu byter vi namn till Translink Corporate Finance

Vi har sedan flera år varit en del av Translink Corporate Finance. Nu tar vi steget fullt ut. Vi kommer även fortsättningsvis ha ett starkt lokalt fokus och engagemang. Den enda skillnaden är till det bättre. Med en starkare internationell förankring kommer vi att kunna ge våra lokala uppdragsgivare ännu bättre service och skapa ännu bättre affärer.

Välkommen till Translink Corporate Finance >>